Details for New Drug Application (NDA): 209305
✉ Email this page to a colleague
The generic ingredient in ESKATA is hydrogen peroxide. There are fifty-three drug master file entries for this compound. Additional details are available on the hydrogen peroxide profile page.
Summary for 209305
Tradename: | ESKATA |
Applicant: | Aclaris |
Ingredient: | hydrogen peroxide |
Patents: | 5 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 209305
Generic Entry Date for 209305*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;TOPICAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Medical Subject Heading (MeSH) Categories for 209305
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;TOPICAL | Strength | 40% | ||||
Approval Date: | Dec 14, 2017 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Subscribe | Patent Expiration: | Apr 21, 2035 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patented Use: | TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED | ||||||||
Patent: | ⤷ Subscribe | Patent Expiration: | Apr 21, 2035 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | ⤷ Subscribe | Patent Expiration: | Apr 21, 2035 | Product Flag? | Y | Substance Flag? | Delist Request? |
Expired US Patents for NDA 209305
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Aclaris | ESKATA | hydrogen peroxide | SOLUTION;TOPICAL | 209305-001 | Dec 14, 2017 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription